Michael D Stein1, Debra S Herman2, Ethan Moitra2, Jacki Hecht3, Rosalie Lopez3, Bradley J Anderson3, Richard A Brown2. 1. Alpert Medical School of Brown University, Department of Medicine, Providence, RI, USA; Butler Hospital, Providence, RI, USA. Electronic address: Michael_Stein@brown.edu. 2. Alpert Medical School of Brown University, Department of Medicine, Providence, RI, USA; Butler Hospital, Providence, RI, USA. 3. Butler Hospital, Providence, RI, USA.
Abstract
BACKGROUND:Buprenorphine opioid agonist treatment (OAT) has established efficacy for treating opioid dependency but early relapse rates are high and are often associated with withdrawal-related or emotional distress. METHODS: To determine whether a novel distress tolerance (DT) intervention during buprenorphine initiation decreases opioid relapse, we conducted a preliminary randomized controlled trial with opioid-dependent outpatients. Participants received buprenorphine-naloxone induction and 3-months of maintenance buprenorphine plus seven, 50-min manualized, individual sessions (DT vs. health education (HE) control) over a 28-day period, linked to clinician medication dosing visits, and beginning 2 days prior to buprenorphine induction. Primary outcomes included use of illicit opioids (positive defined as any self-reported use in the prior 28 days or detected by urine toxicology) and treatment drop out. RESULTS: Among 49 participants, the mean age was 41 years, 65.3% were male. Persons randomized to DT had lower rates of opioid use at all three monthly assessments, and at 3-months, 72% of HE participants were opioid positive compared with 62.5% of DT participants. Rates of dropout were 24% and 25% in the HE and DT arms, respectively. CONCLUSIONS: This distress tolerance treatment produced a small, but not statistically significant reduction in opioid use during the first three months of treatment although no differences were found in drop-out rates between conditions. If replicated in a larger study, DT could offer clinicians a useful behavioral treatment to complement the effects of buprenorphine.
RCT Entities:
BACKGROUND:Buprenorphine opioid agonist treatment (OAT) has established efficacy for treating opioid dependency but early relapse rates are high and are often associated with withdrawal-related or emotional distress. METHODS: To determine whether a novel distress tolerance (DT) intervention during buprenorphine initiation decreases opioid relapse, we conducted a preliminary randomized controlled trial with opioid-dependent outpatients. Participants received buprenorphine-naloxone induction and 3-months of maintenance buprenorphine plus seven, 50-min manualized, individual sessions (DT vs. health education (HE) control) over a 28-day period, linked to clinician medication dosing visits, and beginning 2 days prior to buprenorphine induction. Primary outcomes included use of illicit opioids (positive defined as any self-reported use in the prior 28 days or detected by urine toxicology) and treatment drop out. RESULTS: Among 49 participants, the mean age was 41 years, 65.3% were male. Persons randomized to DT had lower rates of opioid use at all three monthly assessments, and at 3-months, 72% of HE participants were opioid positive compared with 62.5% of DTparticipants. Rates of dropout were 24% and 25% in the HE and DT arms, respectively. CONCLUSIONS: This distress tolerance treatment produced a small, but not statistically significant reduction in opioid use during the first three months of treatment although no differences were found in drop-out rates between conditions. If replicated in a larger study, DT could offer clinicians a useful behavioral treatment to complement the effects of buprenorphine.
Authors: Thomas H Brandon; Thaddeus A Herzog; Laura M Juliano; Jennifer E Irvin; Amy B Lazev; Vani Nath Simmons Journal: J Abnorm Psychol Date: 2003-08
Authors: Richard A Brown; Kathleen M Palm Reed; Erika Litvin Bloom; Haruka Minami; David R Strong; Carl W Lejuez; Christopher W Kahler; Michael J Zvolensky; Elizabeth V Gifford; Steven C Hayes Journal: Nicotine Tob Res Date: 2013-07-24 Impact factor: 4.244
Authors: Mónica Hernández-López; M Carmen Luciano; Jonathan B Bricker; Jesús G Roales-Nieto; Francisco Montesinos Journal: Psychol Addict Behav Date: 2009-12
Authors: Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2010-07-03
Authors: Richard A Brown; C W Lejuez; David R Strong; Christopher W Kahler; Michael J Zvolensky; Linda L Carpenter; Raymond Niaura; Lawrence H Price Journal: Nicotine Tob Res Date: 2009-04-16 Impact factor: 4.244
Authors: Gian-Gabriel P Garcia; Ramin Dehghanpoor; Erin J Stringfellow; Marichi Gupta; Jillian Rochelle; Elizabeth Mason; Toyya A Pujol; Mohammad S Jalali Journal: Int J Environ Res Public Health Date: 2022-05-22 Impact factor: 4.614
Authors: Michael D Stein; Celeste M Caviness; Emily F Morse; Kristin R Grimone; Daniel Audet; Debra S Herman; Ethan Moitra; Bradley J Anderson Journal: Addiction Date: 2017-10-16 Impact factor: 6.526
Authors: Jessica J Wyse; Benjamin J Morasco; Jacob Dougherty; Beau Edwards; Devan Kansagara; Adam J Gordon; P Todd Korthuis; Anaïs Tuepker; Stephan Lindner; Katherine Mackey; Beth Williams; Anders Herreid-O'Neill; Robin Paynter; Travis I Lovejoy Journal: Drug Alcohol Depend Date: 2021-07-29 Impact factor: 4.852
Authors: Gregory L Stuart; Ryan C Shorey; Christopher R France; Jenny Macfie; Kathryn Bell; Kimberly B Fortner; Craig V Towers; Paul Schkolnik; Susan Ramsey Journal: Subst Abuse Date: 2018-08-12
Authors: Valerie J Hruschak; Yan Yuan; Whitney Ringwald; Corinne Beaugard; Melissa Repine; Maria Pacella-LaBarbara; Daniel Rosen; Gerald Cochran Journal: Health Soc Work Date: 2021-08-05
Authors: Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez Journal: Addiction Date: 2021-12-04 Impact factor: 7.256